Namely, PLCβ1 upregulation impairs erythroid differentiation [51], and it has been demonstrated that in low-risk MDS patients responding to erythropoietin, the PI-PLCβ1/cyclin D3 axis is downregulated compared to no responders [52]. The gene discussed is PLCB1; the disease is myelodysplastic syndrome.